Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Data of large-scale research that shows comprehensive abilities of an angiotensin converting enzyme (ACE) inhibitors in clinical practice were rep￾resented. The traditional usage of ACE inhibitors in patients with arterial hypertension and chronic heart failure has extended recently. The study results demonstrate the efficacy of ACE inhibitors in slowing down of disease progression related to atherosclerosis and prove the possibility of a new clinical approach. Evidences support new strategic abilities of a number of ACE inhibitors (ramipril, perindopril), which are associated with vasoprotection.

About the Authors

D. B. Nebieridze
State Research center of preventative medicine of Roszdrav, Moscow
Russian Federation

A. S. Safaryan
State Research center of preventative medicine of Roszdrav, Moscow
Russian Federation


1. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). Комитет экспертов ВНОК. Кардиоваскулярная терапия и профилактика 2004, Приложение.

2. Диагностика и лечение стабильной стенокардии. Российские рекомендации. Комитет экспертов ВНОК. Кардиоваскулярная терапия и профилактика 2004, Приложение.

3. Диагностика и лечение хронической сердечной недостаточности. Российские рекомендации (второй пересмотр).

4. Hansson L, Lindholm LH, Niskanen L et al: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril preven￾tion project (CAPPP) randomized trial. Lancet 1999;353:611-6.

5. Berne C, Pollare T, Lithell H: Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 1991, 14 (suppl 4):39-47.

6. Lithell H: Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991;14:203-209

7. Berne C: Metabolic effects of ACE inhibitors. J Int Med 1991;229 (suppl 2) :119-125.

8. Seghieri G, Yin W, Boni C et al. Effect of chronic ACE inhibition on glucose tolerance and insulin sensitivity in hypertensive type 2 diabetic patients. Diabetic Med 1992;9:732-38.

9. Prince MJ, Stuart CA, Padia M, et al: Metabolic effects of hydrochlorothiazide and enalapril during treatment of the hypertensive diabetic patient. Enalapril for hypertensive diabetics. Arch Intern Med 1998;146:2363-68.

10. Bak JF, Gerdes LU, Sorensen NS et al: Effects of perindopril on insulin sensitivity and plasma lipid profile in hypertensive non-insulin-dependent diabetic patients. Am J Med 1992;92(suppl 4B):69-72.

11. Pool PE, Seagren SC, Salel AF: Metabolic consequences of treating hypertension. Am J Hypertens 1991;4:494-502.

12. N. Kaplan (Ed.). Metabolic aspects of Hypertension. Science Press. 1994, London, UK.

13. Bonner G, Preis S, Schunck U et al. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol 1990;15 (suppl 6): 46–56.

14. Busse R, Lamontagne D. Endothelium–derived bradykinin is responsible for the increase in calcium produced by angiotensin–converting enzyme inhibitors in human endothelial cells. Naunyn–Schmiedebergs Arch Pharmacol 1991;344:126–9.

15. Anderson TJ, Overhiser RW, Haber H, Charbonneau F. A comparative study of four anti–hypertensive agents on endothelial function in patients with coronary disease. J. Am Coll Cardiol. 1998;31 (2, suppl A):32-7A. Abstract.

16. Whitebread S, Mele M, Kamber B, de Gasparo M. Preliminary biochemical characterization of two angiotension II receptor subtypes. Biochemic. Biophys. Res. Commun. 1989;163:284–91.

17. Mancini G, Henry G, Mancaya C et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary disease. The TREND (Trial on reversing Endothelial Dysfunction) study. Circulation 1996; 94: 258-65.

18. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative Study of ACE-inhibition, Angiotensin II Antagonism and Calcium Channel Blockade on Flow-mediated Vasodilation in Patients with coronary Disease (BANFF Study). J. Am. Coll Cardiol. 2000; 35(1): 60-66.

19. НOPE study investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.

20. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomased, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.

21. PEAСE Trial investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058- 2068.

22. Nissen SE, Tuscu EM, Libby P., et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary artery disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-2226.

23. Lonn EM, Yusuf S Dzavic V et al. Effects of ramipril and vitamin E on atherosclerosis: treated with ramipril and vitamin E (SECURE). Circulation 2001;103:919-25

24. HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253- 259.

25. Agodoa LY , Appel L, Barkis GL Effect of ramipril vs amlodipine on renal outcome in hypertensive nephrosclerosis. JAMA 2001; 285:2719-28.

For citation:


Views: 382

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)